

Supplemental Table 1. Unadjusted rates of healthcare utilization by race, ethnicity, and age

Measure	Asian	Black	Hispanic	White
Age <20	N=64	N=86	N=119	N=1148
5ASA	18 (28%)	33 (38%)	44 (37%)	399 (35%)
Advanced medications for IBD	21 (33%)	42 (49%)	52 (44%)	526 (46%)
Immunomodulator therapy	16 (25%)	22 (26%)	37 (31%)	372 (32%)
Corticosteroids	16 (25%)	17 (20%)	40 (34%)	310 (27%)
Intravenous iron	NR	NR	NR	NR
Hospitalization	NR	NR	NR	NR
Emergency department visit for IBD	>4 but <11	>4 but <11	19 (16%)	184 (16%)
Bowel resection surgery	NR	NR	NR	NR
Lower endoscopy	>4 but <11	21 (24%)	35 (29%)	248 (22%)
Abdominal imaging	>4 but <11	>4 but <11	21 (18%)	147 (13%)
Exam under anesthesia	NR	NR	NR	NR
Gastroenterology office visits	40 (63%)	53 (62%)	95 (80%)	862 (75%)
Age 20-64	N=1,052	N=2,295	N=2,261	N=23,346
5ASA	424 (40%)	706 (31%)	791 (35%)	8176 (35%)
Advanced medications for IBD	180 (17%)	508 (22%)	370 (16%)	5172 (22%)
Immunomodulator therapy	142 (14%)	272 (12%)	254 (11%)	3270 (14%)
Corticosteroids	223 (21%)	692 (30%)	545 (24%)	6142 (26%)
Intravenous iron	26 (2%)	38 (2%)	44 (2%)	358 (2%)
Hospitalization	35 (3%)	123 (5%)	96 (4%)	1004 (4%)
Emergency department visit for IBD	84 (8%)	373 (16%)	291 (13%)	2929 (13%)
Bowel resection surgery	>4 but <11	38 (2%)	33 (1%)	355 (2%)
Lower endoscopy	259 (25%)	544 (24%)	457 (20%)	5413 (23%)
Abdominal imaging	58 (6%)	122 (5%)	111 (5%)	1274 (5%)
Exam under anesthesia	>4 but <11	12 (1%)	16 (1%)	123 (1%)
Gastroenterology office visits	485 (46%)	1052 (46%)	911 (40%)	10,474 (45%)
Age 65 or older (CDM)	N=408	N=1,337	N=1,129	N=14,056
5ASA	121 (30%)	485 (36%)	375 (33%)	4589 (33%)
Advanced medications for IBD	12 (3%)	64 (5%)	33 (3%)	713 (5%)
Immunomodulator therapy	18 (4%)	91 (7%)	72 (6%)	1116 (8%)
Corticosteroids	66 (16%)	297 (22%)	205 (18%)	3009 (21%)
Intravenous iron	>4 but <11	29 (2%)	14 (1%)	193 (1%)
Hospitalization	16 (4%)	58 (4%)	41 (4%)	538 (4%)
Emergency department visit for IBD	46 (11%)	219 (16%)	132 (12%)	1698 (12%)
Bowel resection surgery	>4 but <11	11 (1%)	12 (1%)	168 (1%)
Lower endoscopy	73 (18%)	250 (19%)	181 (16%)	2643 (19%)
Abdominal imaging	16 (4%)	69 (5%)	53 (5%)	670 (5%)
Exam under anesthesia	NR	NR	NR	NR
Gastroenterology office visits	129 (32%)	530 (40%)	348 (31%)	5193 (37%)
Age 65 or older (Medicare)	N=814	N=1,632	N=1,364	N=31,063

5ASA	102 (12.5%)	291 (17.8%)	165 (12.1%)	6,561 (21.1%)
Advanced medications for IBD	12 (1.5%)	42 (2.6%)	33 (2.4%)	1,271 (4.1%)
Immunomodulator therapy	25 (3.1%)	48 (2.9%)	39 (2.9%)	1,657 (5.3%)
Corticosteroids	109 (13.4%)	337 (20.6%)	253 (18.5%)	7,939 (25.6%)
Intravenous iron	15 (1.8%)	123 (7.5%)	66 (4.8%)	719 (2.3%)
Hospitalization	NTSR	17 (1.0%)	NTSR	435 (1.4%)
Emergency department visit for IBD	115 (14.1%)	517 (31.7%)	347 (25.4%)	6,369 (20.5%)
Bowel resection surgery	NR	NR	12 (0.9%)	246 (0.8%)
Lower endoscopy	98 (12.0%)	257 (15.7%)	183 (13.4%)	5,027 (16.2%)
Abdominal imaging	34 (4.2%)	79 (4.8%)	71 (5.2%)	1,382 (4.4%)
Exam under anesthesia	NR	NR	NR	37 (0.1%)
Gastroenterology office visits	197 (24.2%)	473 (29.0%)	360 (26.4%)	9,988 (32.2%)

NR – not reported due to small sample size

Supplemental Table 2: Association of race and ethnicity with healthcare use in children

	Asian OR (95% CI)	Black OR (95% CI)	Hispanic OR (95% CI)	Asian (FDR)	Black (FDR)	Hispanic (FDR)
Advanced IBD therapies				.	.	.
Model A	0.60 (0.34-1.08)	1.25 (0.80-1.94)	0.92 (0.60-1.41)	.	.	.
Model B	0.62 (0.35-1.12)	1.26 (0.80-1.97)	0.96 (0.62-1.48)	.	.	.
Model C	0.65 (0.36-1.19)	1.25 (0.80-1.96)	0.98 (0.64-1.52)	.	.	.
Model D	0.65 (0.36-1.18)	1.27 (0.80-2.02)	0.99 (0.64-1.54)	.	.	.
Model E	0.59 (0.33-1.08)	1.36 (0.86-2.14)	1.00 (0.63-1.58)	0.2393	0.4012	0.9931
Model F	0.35 (0.14-0.93)	0.63 (0.28-1.39)	0.91 (0.46-1.80)	0.2391	0.5065	0.8948
Immunomodulators				.	.	.
Model A	0.69 (0.38-1.26)	0.76 (0.46-1.28)	0.93 (0.62-1.38)	.	.	.
Model B	0.67 (0.37-1.23)	0.74 (0.44-1.25)	0.89 (0.60-1.33)	.	.	.
Model C	0.70 (0.38-1.29)	0.74 (0.44-1.26)	0.92 (0.61-1.38)	.	.	.
Model D	0.70 (0.38-1.28)	0.75 (0.44-1.29)	0.93 (0.62-1.39)	.	.	.
Model E	0.67 (0.36-1.24)	0.77 (0.45-1.32)	0.93 (0.62-1.39)	0.4012	0.5894	0.9462
Model F	0.54 (0.24-1.19)	0.87 (0.42-1.81)	1.00 (0.60-1.68)	0.3050	0.8948	0.9995
Mesalamine/Sulfasalazine				.	.	.
Model A	0.61 (0.32-1.15)	1.10 (0.70-1.73)	1.02 (0.66-1.57)	.	.	.
Model B	0.59 (0.31-1.13)	1.03 (0.64-1.64)	1.00 (0.65-1.54)	.	.	.
Model C	0.60 (0.31-1.15)	1.04 (0.65-1.66)	1.02 (0.66-1.57)	.	.	.
Model D	0.61 (0.32-1.16)	1.03 (0.64-1.66)	1.03 (0.66-1.59)	.	.	.
Model E	0.58 (0.30-1.12)	1.06 (0.66-1.68)	1.03 (0.66-1.60)	0.2572	0.9911	0.9911
Model F	0.62 (0.31-1.24)	1.32 (0.79-2.18)	1.03 (0.64-1.64)	0.3786	0.5290	0.9866
Any glucocorticoids				.	.	.
Model A	0.88 (0.48-1.61)	0.65 (0.36-1.17)	1.30 (0.86-1.97)	.	.	.
Model B	0.89 (0.49-1.64)	0.59 (0.33-1.06)	1.32 (0.87-2.02)	.	.	.
Model C	1.05 (0.57-1.94)	0.59 (0.33-1.06)	1.46 (0.95-2.25)	.	.	.
Model D	1.06 (0.58-1.94)	0.59 (0.33-1.06)	1.53 (0.98-2.37)	.	.	.
Model E	1.04 (0.57-1.91)	0.60 (0.33-1.08)	1.53 (0.99-2.37)	0.9911	0.2393	0.2393
Model F	1.17 (0.63-2.16)	0.59 (0.32-1.08)	1.51 (0.94-2.43)	0.8163	0.2391	0.2391

	Asian OR (95% CI)	Black OR (95% CI)	Hispanic OR (95% CI)	Asian (FDR)	Black (FDR)	Hispanic (FDR)
ED visit for IBD or IBD-related diagnosis or abdominal imaging				.	.	.
Model A	0.66 (0.29-1.49)	0.52 (0.25-1.11)	0.97 (0.57-1.64)	.	.	.
Model B	0.65 (0.28-1.47)	0.51 (0.24-1.08)	0.95 (0.56-1.61)	.	.	.
Model C	0.79 (0.35-1.78)	0.52 (0.24-1.11)	1.07 (0.62-1.85)	.	.	.
Model D	0.77 (0.34-1.75)	0.50 (0.23-1.05)	0.99 (0.56-1.75)	.	.	.
Model E	0.76 (0.33-1.76)	0.50 (0.23-1.06)	1.00 (0.56-1.75)	0.7863	0.2393	0.9931
Model F	0.77 (0.33-1.79)	0.50 (0.24-1.07)	0.98 (0.55-1.74)	0.7869	0.2391	0.9872
Lower endoscopy				.	.	.
Model A	0.67 (0.34-1.32)	1.18 (0.70-1.99)	1.43 (0.95-2.16)	.	.	.
Model B	0.67 (0.34-1.33)	1.19 (0.71-2.01)	1.44 (0.95-2.18)	.	.	.
Model C	0.73 (0.37-1.43)	1.13 (0.66-1.94)	1.52 (0.99-2.32)	.	.	.
Model D	0.74 (0.38-1.44)	1.15 (0.66-2.00)	1.59 (1.03-2.45)	.	.	.
Model E	0.71 (0.37-1.38)	1.20 (0.69-2.08)	1.61 (1.04-2.49)	0.5725	0.7863	0.2393
Model F	0.73 (0.37-1.42)	1.18 (0.68-2.07)	1.59 (1.02-2.48)	0.6031	0.7869	0.2391
Cross-sectional abdominal imaging				.	.	.
Model A	1.02 (0.48-2.16)	0.75 (0.35-1.58)	1.50 (0.92-2.44)	.	.	.
Model B	1.01 (0.47-2.15)	0.75 (0.36-1.58)	1.48 (0.91-2.40)	.	.	.
Model C	1.05 (0.49-2.25)	0.73 (0.36-1.51)	1.57 (0.95-2.57)	.	.	.
Model D	1.08 (0.51-2.27)	0.79 (0.38-1.66)	1.70 (1.04-2.80)	.	.	.
Model E	1.06 (0.51-2.22)	0.81 (0.39-1.69)	1.70 (1.03-2.82)	0.9911	0.8105	0.2393
Model F	1.12 (0.53-2.35)	0.77 (0.37-1.60)	1.69 (1.01-2.82)	0.8948	0.7705	0.2391
Any Gastroenterology office visit				.	.	.
Model A	0.53 (0.32-0.91)	0.57 (0.35-0.92)	1.26 (0.79-2.01)	.	.	.
Model B	0.55 (0.33-0.92)	0.55 (0.34-0.89)	1.31 (0.83-2.08)	.	.	.
Model C	0.60 (0.35-1.02)	0.53 (0.33-0.86)	1.39 (0.87-2.22)	.	.	.
Model D	0.60 (0.35-1.03)	0.59 (0.36-0.97)	1.51 (0.95-2.41)	.	.	.

Supplemental Table 3. Association of race and ethnicity with healthcare use in adults aged 20 to 64 years

	Asian OR (95% CI)	Black OR (95% CI)	Hispanic OR (95% CI)	Asian (FDR)	Black (FDR)	Hispanic (FDR)
Advanced IBD therapies				.	.	.
Model A	0.74 (0.62-0.88)	1.00 (0.89-1.11)	0.72 (0.63-0.81)	.	.	.
Model B	0.76 (0.64-0.91)	1.01 (0.91-1.13)	0.74 (0.66-0.84)	.	.	.
Model C	0.79 (0.66-0.93)	1.00 (0.90-1.11)	0.74 (0.66-0.84)	.	.	.
Model D	0.79 (0.66-0.94)	1.02 (0.92-1.14)	0.75 (0.67-0.86)	.	.	.
Model E	0.69 (0.57-0.83)	1.03 (0.91-1.15)	0.74 (0.65-0.84)	0.0013	0.9729	0.0003
Model F	0.95 (0.71-1.26)	1.11 (0.90-1.38)	0.78 (0.62-0.97)	0.9385	0.5453	0.1166
Immunomodulators				.	.	.
Model A	0.99 (0.83-1.19)	0.82 (0.72-0.94)	0.82 (0.71-0.94)	.	.	.
Model B	1.03 (0.86-1.24)	0.89 (0.78-1.02)	0.87 (0.76-1.00)	.	.	.
Model C	1.05 (0.87-1.26)	0.89 (0.78-1.02)	0.87 (0.76-1.01)	.	.	.
Model D	1.05 (0.88-1.27)	0.90 (0.79-1.04)	0.88 (0.77-1.02)	.	.	.
Model E	0.99 (0.82-1.20)	0.90 (0.78-1.04)	0.89 (0.77-1.03)	0.9729	0.3641	0.2973
Model F	1.29 (0.92-1.81)	0.93 (0.75-1.16)	1.04 (0.83-1.31)	0.3264	0.8600	0.9385
Mesalamine/Sulfasalazine						
Model A	1.13 (0.99-1.29)	0.83 (0.76-0.92)	0.89 (0.81-0.98)	.	.	.
Model B	1.12 (0.98-1.29)	0.84 (0.76-0.93)	0.89 (0.81-0.98)	.	.	.
Model C	1.13 (0.99-1.30)	0.84 (0.76-0.93)	0.90 (0.82-0.99)	.	.	.
Model D	1.13 (0.99-1.29)	0.87 (0.78-0.96)	0.91 (0.83-1.00)	.	.	.
Model E	1.09 (0.95-1.25)	0.86 (0.78-0.96)	0.92 (0.83-1.01)	0.3822	0.0310	0.2415
Model F	1.04 (0.90-1.19)	0.86 (0.77-0.95)	0.89 (0.81-0.98)	0.9345	0.0369	0.1076
Any steroids						
Model A	0.77 (0.66-0.89)	1.21 (1.10-1.33)	0.89 (0.81-0.99)	.	.	.
Model B	0.80 (0.68-0.92)	1.11 (1.01-1.22)	0.88 (0.79-0.98)	.	.	.
Model C	0.87 (0.74-1.01)	1.08 (0.98-1.19)	0.89 (0.80-0.98)	.	.	.
Model D	0.86 (0.74-1.01)	1.06 (0.96-1.17)	0.88 (0.79-0.98)	.	.	.
Model E	0.84 (0.72-0.97)	1.06 (0.96-1.18)	0.88 (0.79-0.98)	0.0979	0.4187	0.0979
Model F	0.83 (0.71-0.97)	1.06 (0.96-1.18)	0.88 (0.79-0.98)	0.1076	0.4555	0.1076
IV iron				.	.	.

	Asian OR (95% CI)	Black OR (95% CI)	Hispanic OR (95% CI)	Asian (FDR)	Black (FDR)	Hispanic (FDR)
Model A	1.81 (1.21-2.72)	1.05 (0.75-1.47)	1.35 (0.98-1.86)	.	.	.
Model B	1.89 (1.25-2.84)	1.00 (0.71-1.40)	1.36 (0.99-1.88)	.	.	.
Model C	2.03 (1.34-3.08)	0.97 (0.69-1.37)	1.37 (0.99-1.89)	.	.	.
Model D	1.99 (1.31-3.02)	1.03 (0.73-1.45)	1.38 (1.00-1.92)	.	.	.
Model E	1.94 (1.28-2.93)	1.02 (0.71-1.45)	1.41 (1.02-1.96)	0.0128	0.9729	0.1350
Model F	2.04 (1.35-3.09)	1.03 (0.73-1.46)	1.46 (1.05-2.02)	0.0280	0.9385	0.1119
Hospitalization for IBD				.	.	.
Model A	0.82 (0.58-1.16)	1.26 (1.03-1.53)	1.06 (0.85-1.33)	.	.	.
Model B	0.85 (0.60-1.21)	1.19 (0.98-1.45)	1.06 (0.85-1.32)	.	.	.
Model C	0.92 (0.64-1.31)	1.13 (0.92-1.38)	1.05 (0.84-1.32)	.	.	.
Model D	0.93 (0.65-1.33)	1.00 (0.81-1.23)	0.98 (0.78-1.23)	.	.	.
Model E	0.89 (0.62-1.27)	0.98 (0.80-1.21)	0.99 (0.79-1.24)	0.7828	0.9729	0.9729
Model F	0.91 (0.64-1.31)	0.99 (0.80-1.22)	1.01 (0.81-1.27)	0.9345	0.9385	0.9385
Emergency department visit for IBD or IBD-related diagnosis or abdominal imaging				.	.	.
Model A	0.64 (0.51-0.80)	1.34 (1.19-1.51)	1.07 (0.94-1.22)	.	.	.
Model B	0.65 (0.52-0.82)	1.29 (1.15-1.46)	1.07 (0.94-1.22)	.	.	.
Model C	0.71 (0.56-0.90)	1.24 (1.09-1.40)	1.08 (0.94-1.23)	.	.	.
Model D	0.71 (0.56-0.89)	1.10 (0.97-1.24)	1.01 (0.88-1.15)	.	.	.
Model E	0.69 (0.55-0.87)	1.09 (0.96-1.24)	1.01 (0.88-1.15)	0.0128	0.3822	0.9729
Model F	0.70 (0.55-0.88)	1.09 (0.96-1.24)	1.02 (0.89-1.16)	0.0369	0.3750	0.9385
Bowel resection surgery				.	.	.
Model A	0.59 (0.30-1.14)	1.10 (0.78-1.54)	1.01 (0.71-1.45)	.	.	.
Model B	0.63 (0.32-1.22)	1.07 (0.76-1.50)	1.05 (0.73-1.50)	.	.	.
Model C	0.66 (0.34-1.28)	1.03 (0.73-1.44)	1.04 (0.72-1.49)	.	.	.
Model D	0.67 (0.34-1.31)	0.98 (0.69-1.39)	1.01 (0.70-1.45)	.	.	.
Model E	0.65 (0.33-1.26)	0.98 (0.69-1.39)	1.04 (0.72-1.49)	0.3822	0.9729	0.9729
Model F	0.67 (0.34-1.32)	0.99 (0.69-1.40)	1.07 (0.75-1.54)	0.4555	0.9385	0.9385
Lower endoscopy				.	.	.
Model A	1.10 (0.95-1.27)	1.04 (0.94-1.15)	0.84 (0.75-0.94)	.	.	.
Model B	1.11 (0.96-1.28)	1.05 (0.95-1.17)	0.86 (0.77-0.95)	.	.	.

[illegible]

Supplemental Table 4. Association of race and medication use in adults aged 65 or older

	Asian OR (95% CI)	Black OR (95% CI)	Hispanic OR (95% CI)	Asian (FDR)	Black (FDR)	Hispanic (FDR)
Advanced IBD therapies				.	.	.
Model A	0.52 (0.34-0.79)	0.76 (0.50-1.15)	0.64 (0.50-0.84)	.	.	.
Model B	0.55 (0.33-0.92)	0.77 (0.52-1.13)	0.70 (0.54-0.91)	.	.	.
Model C	0.55 (0.34-0.90)	0.77 (0.55-1.09)	0.70 (0.54-0.91)	.	.	.
Model D	0.61 (0.40-0.93)	0.86 (0.65-1.13)	0.80 (0.62-1.05)	.	.	.
Model E	0.59 (0.38-0.92)	0.83 (0.64-1.08)	0.78 (0.59-1.03)	0.1122	0.3492	0.2032
Model F	0.55 (0.34-0.90)	0.70 (0.52-0.93)	0.76 (0.52-1.11)	0.0977	0.0977	0.3216
Immunomodulators				.	.	.
Model A	0.62 (0.45-0.84)	0.68 (0.43-1.08)	0.72 (0.50-1.03)	.	.	.
Model B	0.63 (0.46-0.86)	0.71 (0.46-1.10)	0.73 (0.49-1.10)	.	.	.
Model C	0.62 (0.45-0.85)	0.72 (0.51-1.02)	0.74 (0.53-1.03)	.	.	.
Model D	0.68 (0.49-0.94)	0.78 (0.60-1.02)	0.82 (0.67-1.01)	.	.	.
Model E	0.67 (0.48-0.93)	0.77 (0.59-0.99)	0.81 (0.65-1.00)	0.1121	0.1394	0.1632
Model F	0.53 (0.30-0.94)	0.75 (0.54-1.03)	0.71 (0.48-1.06)	0.1079	0.2003	0.2399
Mesalamine/Sulfasalazine				.	.	.
Model A	0.68 (0.45-1.02)	0.98 (0.71-1.35)	0.73 (0.39-1.38)	.	.	.
Model B	0.69 (0.46-1.04)	0.98 (0.72-1.34)	0.75 (0.40-1.41)	.	.	.
Model C	0.67 (0.45-1.00)	0.97 (0.80-1.18)	0.73 (0.42-1.28)	.	.	.
Model D	0.68 (0.50-0.93)	1.02 (0.84-1.23)	0.77 (0.46-1.27)	.	.	.
Model E	0.68 (0.49-0.96)	1.00 (0.81-1.23)	0.75 (0.44-1.29)	0.1284	0.9953	0.5029
Model F	0.68 (0.49-0.95)	1.01 (0.82-1.24)	0.75 (0.44-1.29)	0.1079	0.9849	0.5283
Any steroids				.	.	.
Model A	0.58 (0.38-0.87)	0.88 (0.66-1.17)	0.74 (0.62-0.89)	.	.	.
Model B	0.62 (0.40-0.96)	0.79 (0.65-0.97)	0.77 (0.67-0.88)	.	.	.
Model C	0.59 (0.37-0.93)	0.75 (0.65-0.85)	0.70 (0.58-0.84)	.	.	.
Model D	0.63 (0.45-0.86)	0.78 (0.71-0.86)	0.75 (0.67-0.84)	.	.	.
Model E	0.62 (0.45-0.86)	0.77 (0.70-0.85)	0.75 (0.67-0.84)	0.0317	<.0001	<.0001
Model F	0.67 (0.50-0.89)	0.83 (0.75-0.91)	0.78 (0.70-0.88)	0.0439	0.0015	0.0012
IV iron				.	.	.

	Asian OR (95% CI)	Black OR (95% CI)	Hispanic OR (95% CI)	Asian (FDR)	Black (FDR)	Hispanic (FDR)
Model A	0.96 (0.61-1.51)	2.40 (1.16-4.97)	1.50 (0.66-3.45)	.	.	.
Model B	0.99 (0.64-1.52)	2.28 (1.03-5.03)	1.62 (0.75-3.49)	.	.	.
Model C	1.07 (0.69-1.65)	2.11 (0.99-4.49)	1.61 (0.81-3.18)	.	.	.
Model D	1.07 (0.66-1.73)	2.03 (0.94-4.38)	1.55 (0.80-3.03)	.	.	.
Model E	1.06 (0.65-1.74)	2.02 (0.92-4.43)	1.56 (0.81-3.02)	0.8936	0.2032	0.3492
Model F	1.08 (0.65-1.80)	2.04 (0.94-4.43)	1.58 (0.83-3.01)	0.9489	0.2003	0.3216
Hospitalization for IBD				.	.	.
Model A	0.76 (0.35-1.67)	0.97 (0.63-1.49)	0.71 (0.33-1.53)	.	.	.
Model B	0.78 (0.34-1.78)	0.97 (0.62-1.51)	0.73 (0.32-1.66)	.	.	.
Model C	0.83 (0.37-1.88)	0.92 (0.57-1.46)	0.73 (0.31-1.70)	.	.	.
Model D	0.91 (0.46-1.80)	0.96 (0.69-1.33)	0.78 (0.40-1.55)	.	.	.
Model E	0.91 (0.45-1.86)	0.98 (0.75-1.27)	0.78 (0.37-1.65)	0.8936	0.9092	0.7101
Model F	0.98 (0.53-1.80)	1.01 (0.78-1.29)	0.79 (0.38-1.66)	0.9849	0.9849	0.7459
Emergency department visit for IBD or IBD-related diagnosis or abdominal imaging				.	.	.
Model A	0.74 (0.49-1.13)	1.63 (1.35-1.97)	1.13 (0.85-1.49)	.	.	.
Model B	0.77 (0.50-1.20)	1.57 (1.25-1.98)	1.18 (0.92-1.50)	.	.	.
Model C	0.77 (0.47-1.26)	1.49 (1.24-1.79)	1.12 (0.97-1.30)	.	.	.
Model D	0.74 (0.40-1.35)	1.43 (1.22-1.67)	1.06 (0.95-1.18)	.	.	.
Model E	0.74 (0.40-1.35)	1.41 (1.19-1.67)	1.05 (0.94-1.18)	0.5127	0.0006	0.5450
Model F	0.75 (0.41-1.36)	1.43 (1.19-1.71)	1.07 (0.95-1.20)	0.5681	0.0015	0.4579
Bowel resection surgery				.	.	.
Model A	0.83 (0.43-1.62)	0.73 (0.47-1.13)	1.02 (0.67-1.54)	.	.	.
Model B	0.85 (0.44-1.65)	0.74 (0.48-1.14)	1.04 (0.68-1.58)	.	.	.
Model C	0.90 (0.46-1.76)	0.66 (0.43-1.02)	1.01 (0.67-1.55)	.	.	.
Model D	0.98 (0.49-1.95)	0.70 (0.45-1.08)	1.10 (0.72-1.69)	.	.	.
Model E	0.97 (0.49-1.92)	0.70 (0.45-1.09)	1.11 (0.72-1.71)	0.9551	0.2719	0.7997
Model F	0.99 (0.50-1.95)	0.72 (0.46-1.12)	1.13 (0.74-1.73)	0.9849	0.3216	0.7521
Lower endoscopy				.	.	.
Model A	0.85 (0.72-1.00)	0.98 (0.88-1.09)	0.86 (0.76-0.96)	.	.	.
Model B	0.86 (0.71-1.04)	0.97 (0.87-1.07)	0.89 (0.79-1.00)	.	.	.

[illegible]